Tagged News
Lymphodepletion Enhances MAR-T Cell Therapy Efficacy in Lymphoma Patients, Marker Therapeutics Reports
• Marker Therapeutics' Phase 1 APOLLO study shows lymphodepletion significantly improves expansion and persistence of MT-601 MAR-T cells in lymphoma patients, potentially enhancing anti-tumor activity.
• Early clinical data reveals promising efficacy with 78% objective response rate and 44.4% complete response rate in patients who relapsed after or are not candidates for anti-CD19 CAR-T therapy.
• The non-genetically modified MAR-T cell approach targets six different tumor antigens, demonstrating excellent safety with no dose-limiting toxicities while potentially offering manufacturing advantages over current engineered T cell therapies.
Related Clinical Trials:
Marker Therapeutics, Inc.
Posted 1/2/2023
Novel BAFF-R CAR-T Therapy Achieves Complete Response in Heavily Pretreated Follicular Lymphoma Patient
• PeproMene Bio's first-in-class BAFF-R targeted CAR-T cell therapy (PMB-CT01) has achieved complete remission in a heavily pretreated follicular lymphoma patient who had failed seven prior therapies including CD19 CAR-T.
• All seven patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with PMB-CT01 have achieved complete responses lasting from 1 to 29+ months, with minimal toxicity reported.
• PMB-CT01 targets the BAFF receptor, which is crucial for B-cell survival, potentially making it harder for tumor cells to escape therapy through antigen loss compared to CD19-targeted approaches.
Related Clinical Trials:
PeproMene Bio, Inc.
Posted 5/18/2021
PeproMene Bio, Inc.
Posted 6/13/2022
KaliVir Advances Novel Oncolytic Immunotherapy VET3-TGI in Phase 1/1b Trial for Advanced Solid Tumors
• KaliVir Immunotherapeutics has successfully completed the first cohort of its STEALTH-001 Phase 1/1b trial evaluating VET3-TGI in patients with advanced solid tumors.
• The Data Safety Committee has reviewed safety data and cleared dosing for the next intratumoral and intravenous cohorts, allowing the trial to progress to higher dose levels.
• VET3-TGI is a novel oncolytic immunotherapy designed to selectively kill tumor cells while delivering an immuno-stimulatory payload of interleukin-12 and a TGFbeta inhibitor.
Related Clinical Trials:
KaliVir Immunotherapeutics
Posted 9/16/2024
PharmaEssentia's Ropeginterferon Shows Promising Results in Phase 3 Trial for Essential Thrombocythemia
• PharmaEssentia will present positive Phase 3 SURPASS-ET trial results showing ropeginterferon alfa-2b-njft achieved significantly higher durable clinical response rates compared to anagrelide (42.9% vs. 6.0%; p=0.0001) in essential thrombocythemia patients.
• The trial demonstrated not only effective blood count control but also a measurable reduction in JAK2 mutation allele burden over 12 months, addressing an underlying disease mechanism that current treatments fail to target.
• Ropeginterferon alfa-2b-njft (marketed as BESREMi® for polycythemia vera) could potentially offer a new second-line treatment option for essential thrombocythemia, a rare blood disorder characterized by excessive platelet production.
Related Clinical Trials:
PharmaEssentia
Posted 8/25/2020
Eisai to Present Long-Term LEAP-002 Data and Novel Pipeline Advances at ASCO 2025
• Eisai will showcase long-term follow-up data from the Phase 3 LEAP-002 study evaluating lenvatinib plus pembrolizumab versus lenvatinib monotherapy in first-line unresectable hepatocellular carcinoma treatment.
• The company will present research on E7386, a CBP/β-catenin interaction inhibitor, in combination with lenvatinib for patients with advanced or recurrent endometrial carcinoma, addressing significant unmet medical needs.
• Final analysis data from the Phase 3 LEAP-015 study examining lenvatinib plus pembrolizumab and chemotherapy in advanced gastroesophageal adenocarcinoma will be featured in an oral presentation.
Related Clinical Trials:
Merck Sharp & Dohme LLC
Posted 12/30/2020
Eisai Inc.
Posted 7/11/2019
Biostate AI Secures $12M Series A to Revolutionize RNA Sequencing and Molecular Diagnostics
• Biostate AI has raised $12 million in Series A funding led by Accel to develop affordable RNA sequencing technology and AI-powered diagnostic models.
• The company's proprietary BIRT and PERD technologies reduce RNAseq costs by nearly an order of magnitude, enabling researchers to run 2-3 times more samples within existing budgets.
• Founded by former professors David Zhang and Ashwin Gopinath, Biostate AI aims to build "foundation models" for molecular medicine by analyzing billions of RNA expressions to predict disease evolution and drug responses.
FDA Greenlights Promontory Therapeutics' Phase 3 Trial Design for PT-112 in Metastatic Prostate Cancer
• Promontory Therapeutics has successfully completed an End of Phase 2 meeting with the FDA, reaching agreement on key aspects of a registrational Phase 3 trial for PT-112 in metastatic castration-resistant prostate cancer.
• The FDA approved the proposed dosing regimen, patient population, study comparator, and endpoints, with an interim analysis provision that could allow for drug approval before study completion.
• Preliminary clinical outcomes from the Phase 2 trial of PT-112 will be presented at the upcoming ASCO 2025 Annual Meeting on June 2nd, following recent presentation of immune response biomarker data at AACR 2025.
Related Clinical Trials:
National Cancer Institute (NCI)
Posted 4/6/2022
Promontory Therapeutics Inc.
Posted 7/1/2014
ACT Technology Shows Promising Results in Enhancing Chemotherapy for Colorectal Liver Metastases
• EXACT Therapeutics' Phase 1 ACTIVATE trial demonstrates that Acoustic Cluster Therapy (ACT) significantly enhances chemotherapy effectiveness, with ACT-treated tumors showing 29% reduction in diameter compared to 7% with chemotherapy alone.
• The innovative treatment demonstrated a clear dose-response relationship, with higher doses (40 μl/kg) of PS101 producing greater tumor shrinkage than lower doses (20 μl/kg), while maintaining an excellent safety profile.
• These positive results support advancement to the Phase 2 ENACT trial targeting pancreatic cancer, potentially offering new hope for patients with difficult-to-treat solid tumors.
Related Clinical Trials:
EXACT Therapeutics AS
Posted 9/17/2019
Minghui Pharmaceutical Initiates Phase II Trial Combining PD-1xVEGF Bispecific with TROP-2 ADC for Advanced NSCLC
• Minghui Pharmaceutical has dosed the first patient in a Phase II trial evaluating the combination of MHB039A (PD-1xVEGF bispecific antibody) and MHB036C (TROP-2 ADC) in advanced non-small cell lung cancer patients.
• MHB039A demonstrated full blocking activities against both targets with superior PD-1 activity compared to competitors, while MHB036C showed promising anti-tumor activity in heavily pre-treated NSCLC and breast cancer patients.
• The novel combination approach aims to achieve more robust and durable anti-tumor responses, potentially reshaping standard-of-care treatment paradigms for NSCLC and other solid tumors.
Safety Concerns Emerge for Gold-Based Cisplatin Mimics in Cancer Treatment Development
• Researchers from King's College London and Jagannath University discovered that gold-based cisplatin mimics contain a mixture of potentially dangerous isomers rather than a pure compound as previously believed for over 60 years.
• The gold(III) dithiocarbamate compounds, which promised fewer side effects than traditional chemotherapy, were found to produce positively charged molecules instead of the neutral ones reported in previous studies.
• This finding challenges nearly 100 scientific publications and raises significant safety concerns as these compounds have not been properly tested for toxicity in their actual mixed form.